CryoLife, Inc. (CRY) Updates FY17 Earnings Guidance

CryoLife, Inc. (NYSE:CRY) issued an update on its FY17 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $40-0.43 for the period, compared to the Thomson Reuters consensus estimate of $0.43. The company issued revenue guidance of $188-192 million, compared to the consensus revenue estimate of $189.31 million.

Shares of CryoLife, Inc. (CRY) opened at 19.05 on Friday. CryoLife, Inc. has a one year low of $14.02 and a one year high of $20.30. The company has a market capitalization of $637.15 million, a PE ratio of 57.73 and a beta of 0.97. The company’s 50-day moving average is $19.18 and its 200-day moving average is $17.98.

CryoLife (NYSE:CRY) last announced its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.02. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The business had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $47.02 million. During the same period in the previous year, the business posted $0.13 EPS. The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. Equities analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current year.

A number of equities research analysts recently issued reports on CRY shares. Zacks Investment Research upgraded CryoLife from a hold rating to a buy rating and set a $21.00 price objective on the stock in a research note on Thursday, June 8th. Northland Securities reiterated a buy rating and set a $23.50 price target on shares of CryoLife in a research report on Friday, April 28th. Finally, BidaskClub cut CryoLife from a buy rating to a hold rating in a research report on Monday, July 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $22.00.

In other news, VP Amy Horton sold 9,577 shares of the company’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $20.00, for a total transaction of $191,540.00. Following the sale, the vice president now directly owns 112,282 shares in the company, valued at $2,245,640. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 6.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “CryoLife, Inc. (CRY) Updates FY17 Earnings Guidance” was first published by BNB Daily and is the sole property of of BNB Daily. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/19/cryolife-inc-cry-updates-fy17-earnings-guidance-updated-updated-updated.html.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Earnings History and Estimates for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply